Modified immune cells for advanced stomach cancer
Part of Cancer, Digestive system clinical trials.
This early-phase trial tests a new type of immune cell therapy (TCRx T cells) for advanced stomach cancer that has not responded to standard chemotherapy. The goal is to see if these specially engineered cells can help your body fight the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 70 years old.
- You have gastric (stomach) or gastroesophageal junction cancer that has progressed after initial chemotherapy or returned after surgery and chemo.
- You are in reasonably good health (able to care for yourself, ECOG 0-2).
- You have at least one tumor that can be measured on imaging (larger than 1 cm).
- Your blood counts, liver, and kidney function are within acceptable ranges.
- You agree to use contraception during the study and for 6 months after.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of fecal microbiota transplant (FMT), chemotherapy (SOX), and an immunotherapy drug (Sintilimab) as a first treatment for advanced stomach or gastroesophageal junction cancer that cannot be removed by surgery. The goal is to see if this combination can shrink tumors and improve outcomes.
This trial tests a combination of low-dose radiation, chemotherapy, and an immunotherapy drug (AK112) for people with advanced stomach or gastroesophageal junction cancer that has progressed after first-line treatment. The goal is to see if this combination can help shrink tumors or slow the cancer's growth.
This study tests whether giving treatment based on the specific markers of your tumor can better control advanced stomach cancer. The goal is to match the right therapy to each person's cancer.
This trial tests a combination of an immunotherapy drug (sintilimab) and two chemotherapy drugs (nab-paclitaxel and tegafur) as a first treatment for stomach or gastroesophageal junction cancer that cannot be removed by surgery or has spread. The goal is to see if this combination helps people live longer and controls the cancer better.
This trial tests a combination of three drugs—adebrelimab (an immunotherapy), fruquintinib (a targeted therapy to cut off blood supply to the tumor), and a chemotherapy (paclitaxel or albumin-bound paclitaxel)—in people with advanced stomach/gastric cancer whose disease has worsened after one prior chemotherapy. The goal is to see if this new mix can help control the cancer.
This trial tests a special type of immune cell therapy for people with advanced gastric cancer. The treatment uses your own immune cells that are specially trained to find and attack cancer cells. It may help when standard treatments have stopped working.
Hear when a new Gastric Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.